Cellectar Biosciences (CLRB) Cash from Investing Activities (2011 - 2024)
Cellectar Biosciences (CLRB) posted Cash from Investing Activities of -$61286.0 for Q4 2024, down 188.05% sequentially from -$21276.0 in Q2 2024, and up 77.03% YoY from -$34619.9 in Q1 2024.
Cellectar Biosciences (CLRB) Cash from Investing Activities (2011 - 2024) Analysis & Trends
Cellectar Biosciences has reported Cash from Investing Activities for 14 years, with the latest figure at -$61286.0 in Q4 2024.
- Quarterly Cash from Investing Activities rose 77.03% year-over-year to -$61286.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$104195.0 (up 77.48% YoY) and the FY2025 annual result came in at -$5880.0, up 94.36% from the prior year.
- Cash from Investing Activities declined to -$61286.0 in Q4 2024 per CLRB's latest filing, from -$21276.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$4063.0 in Q3 2021 and troughed at -$266756.0 in Q4 2023.
- A 5-year average of -$61005.9 and a median of -$30070.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2021 and 2024: Cash from Investing Activities tumbled 653.86% in 2021, then jumped 77.03% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$17210.0 in 2020, then sank by 653.86% to -$129739.0 in 2021, then gained by 9.16% to -$117856.0 in 2022, then plunged by 126.34% to -$266756.0 in 2023, then surged by 77.03% to -$61286.0 in 2024.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$61286.0, -$21276.0, and -$21633.0 for Q4 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -61,286.00 |
| Dec 31, 2024 | -61,286.00 |
| Jun 30, 2024 | -21,276.00 |
| Jun 30, 2024 | -21,276.00 |
| Mar 31, 2024 | -21,633.00 |
| Mar 31, 2024 | -21,633.00 |
| Dec 31, 2023 | -266,756.00 |
| Dec 31, 2023 | -266,756.00 |
| Dec 31, 2022 | -117,856.00 |
| Dec 31, 2022 | -117,856.00 |
| Sep 30, 2022 | -7,066.00 |
| Sep 30, 2022 | -7,066.00 |
| Jun 30, 2022 | -70,979.00 |
| Jun 30, 2022 | -70,979.00 |
| Mar 31, 2022 | -30,070.00 |
| Mar 31, 2022 | -30,070.00 |
| Dec 31, 2021 | -129,739.00 |
| Dec 31, 2021 | -129,739.00 |
| Sep 30, 2021 | -4,063.00 |
| Sep 30, 2021 | -4,063.00 |